Evidence map›Paper›PMID 26823715›Full record

ArticleInternational journal of clinical and experimental pathology2015

Modulatory role of garlicin in migration and invasion of intrahepatic cholangiocarcinoma via PI3K/AKT pathway.

Kun Xie, Jianze Nian, Xingyang Zhu, Xiaoping Geng, Fubao Liu

Open access · greenAbstract read
In one paragraph

Article in International journal of clinical and experimental pathology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.1field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Kun XieDepartment of General Surgery, The First Affiliated Hospital of Medical University of Anhui Hefei 230022, Anhui, China.
Jianze NianDepartment of General Surgery, The First Affiliated Hospital of Medical University of Anhui Hefei 230022, Anhui, China.
Xingyang ZhuDepartment of General Surgery, The First Affiliated Hospital of Medical University of Anhui Hefei 230022, Anhui, China.
Xiaoping GengDepartment of General Surgery, The First Affiliated Hospital of Medical University of Anhui Hefei 230022, Anhui, China.
Fubao LiuDepartment of General Surgery, The First Affiliated Hospital of Medical University of Anhui Hefei 230022, Anhui, China.
Anhui Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Increasing evidences have indicated the role of garlicin in inhibiting the progression of various tumors including glioma, pulmonary carcinoma and pancreatic carcinoma, via mediating cell apoptosis or cell cycle. The regulatory effect and related molecular mechanism of garlicin in intrahepatic cholangiocarcinoma, however, remained unknown. This study thus aimed to investigate this scientific issue. HCCC-9810 cell line was treated with serially diluted garlicin, followed by cell proliferation assay using MTT approach. Transwell migration and invasion assays were further employed the regulatory effect of garlicin. The expression level of p-AKT and AKT proteins in tumor cells was quantified by Western blot. The growth of tumor cells was significantly inhibited by high concentration of garlicin (> 1.5 μM). Lower concentration of garlicin showed dose-dependent inhibition of tumor cell invasion and migration. After using specific agonist IGF-1 (50 ng/mL) of PI3K/AKT signaling pathway, such facilitating effects of garlicin were depressed (P < 0.05). Western blotting showed significantly decreased phosphorylation level of AKT after treated with gradient concentrations of garlicin, while leaving the total AKT protein level unchanged. Garlicin may inhibit the invasion and migration of intrahepatic cholangiocarcinoma cells via inhibiting PI3K/AKT signaling pathway.

Indexed as

Allyl CompoundsAntineoplastic Agents, PhytogenicBile Duct NeoplasmsCell Line, TumorCell MovementCell ProliferationCholangiocarcinomaDisulfidesDose-Response Relationship, DrugHumansNeoplasm InvasivenessPhosphatidylinositol 3-KinasePhosphoinositide-3 Kinase InhibitorsPhosphorylationProtein Kinase InhibitorsProto-Oncogene Proteins c-aktAllyl CompoundsAntineoplastic Agents, Phytogenicdiallyl disulfideDisulfidesPhosphatidylinositol 3-KinasePhosphoinositide-3 Kinase InhibitorsProtein Kinase InhibitorsProto-Oncogene Proteins c-aktGarlicinintrahepatic cholangiocarcinomaPI3K/AKT signaling pathwaytumor invasiontumor migration

Identifiers

PMID26823715
PMCPMC4713501
OpenAlexW2414274179

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.